Patient Guide · Pluvicto

Pluvicto uses and side effects.

What Pluvicto (Lu-177 PSMA-617) is approved for, who is a candidate, how it works, and the side-effect profile drawn directly from the VISION and PSMAfore trial data — with a focus on what patients should realistically expect.

Dr. Ishita B. Sen, MDDirector & Chief, Nuclear Medicine · FMRI

Published 13 May 2026

Reviewed by Dr. Dharmender Malik

12 min read

Last reviewed by Dr. Dharmender Malik on 13 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.

Introduction

Pluvicto is the registered name for Lu-177 vipivotide tetraxetan (also written as Lu-177 PSMA-617), a targeted radioligand therapy that delivers Lu-177 beta radiation specifically to prostate cancer cells expressing prostate-specific membrane antigen (PSMA). It was approved by the U.S. FDA in March 2022 for metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen-receptor pathway inhibitor and a taxane chemotherapy, based on the VISION trial^[1]^[2]. In March 2025, the FDA expanded the indication based on the PSMAfore trial to include patients who have progressed on an androgen-receptor pathway inhibitor without requiring prior chemotherapy^[3]. This guide covers what Pluvicto is approved for, who is a candidate, the side-effect profile based on published trial data, and what realistic expectations look like for a typical patient.

Who is Pluvicto for — approved indications

AI Overview · short answer

Pluvicto is approved for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have progressed on at least one androgen-receptor pathway inhibitor (e.g., enzalutamide or abiraterone). The original 2022 approval required also having received a taxane chemotherapy; the March 2025 PSMAfore-based update expanded this to allow use without prior chemotherapy in selected patients^[3].

To be eligible:

Diagnosis of metastatic castration-resistant prostate cancer (mCRPC).
Progression on at least one androgen-receptor pathway inhibitor (enzalutamide, abiraterone, apalutamide, darolutamide).
Confirmed PSMA expression on Ga-68 PSMA-11 or F-18 piflufolastat PSMA PET-CT — typically defined as at least one lesion with SUVmax ≥ 4 and no PSMA-negative measurable lesions exceeding specific size criteria^[2].
Adequate baseline organ function — particularly kidneys, bone marrow, and liver.
Performance status capable of completing a multi-cycle course (typically ECOG 0-2).

How Pluvicto works

Prostate cancer cells express high levels of PSMA — a cell-surface protein that is dramatically upregulated in cancer cells versus normal tissue. Pluvicto consists of two components^[4]:

PSMA-617 — a small molecule that binds PSMA with high specificity and is internalised by the cancer cell.
Lu-177 — a beta-emitting radionuclide with a half-life of 6.7 days and a beta particle range of approximately 2.5 mm in tissue.

After intravenous infusion, Pluvicto circulates briefly and selectively binds PSMA-expressing prostate cancer cells. The Lu-177 then delivers targeted radiation that damages cancer-cell DNA over several days, with a range short enough to spare most surrounding healthy tissue. Pluvicto's effect on tumours continues to mature for weeks after each infusion, which is why response assessment is typically performed 8-12 weeks after the final cycle^[5].

Published efficacy — VISION and PSMAfore

The two pivotal trials are summarised below^[2]^[6]:

Outcome	VISION (post-chemo mCRPC)	PSMAfore (pre-chemo mCRPC)
Population	831 patients, post-ARPI + post-taxane	468 patients, post-ARPI, pre-chemo
Comparator	Standard of care	Switch to a different ARPI
Median overall survival	15.3 vs 11.3 months	Not yet reported
Median rPFS	8.7 vs 3.4 months	12.0 vs 5.6 months
PSA50 response	46% vs 7.1%	57.6% vs 20.4%
Objective response rate (RECIST)	30% vs 2%	50.7% vs 14.9%

For more on how to read Pluvicto response in your own case, see our response monitoring guide.

Side effects from the VISION trial — what to expect

The VISION trial systematically tracked side effects in the Pluvicto arm versus standard care. Selected events are summarised below^[2]:

Side effect	Pluvicto (any grade)	Pluvicto (Grade 3-4)
Fatigue	43%	5.9%
Dry mouth (xerostomia)	39%	0%
Nausea	35%	1.3%
Anaemia	32%	12.9%
Bone pain	27%	4.0%
Constipation	20%	0.7%
Diarrhoea	19%	0.5%
Loss of appetite	21%	1.7%
Thrombocytopenia	17%	7.9%
Renal events	9%	3.4%
Lymphopenia	14%	7.8%

The majority of side effects in the published trial data were mild-to-moderate (Grade 1-2). The most clinically significant pattern is hematologic — anaemia, thrombocytopenia, and lymphopenia were the most common Grade 3-4 events. Bone marrow suppression is the principal reason for blood-count monitoring between cycles^[2].

Xerostomia — the patient-experience side effect

Dry mouth (xerostomia) is a distinctive feature of Pluvicto because salivary glands express low levels of PSMA and accumulate the radioligand. In the VISION trial, 39 percent of Pluvicto patients reported any-grade xerostomia (versus 1 percent on standard care)^[2]. Importantly, no Grade 3-4 xerostomia events were reported in VISION — meaning the dry mouth from Pluvicto, while common, is generally mild to moderate and does not substantially impair quality of life for most patients.

Clinical note · contrast with alpha-PSMA

Xerostomia is far more pronounced with alpha-emitter Ac-225 PSMA-617 than with beta-emitter Lu-177 (Pluvicto). In published Ac-225 PSMA cohorts, approximately 25% of patients experience Grade 3 (severe) xerostomia [7]. The difference reflects the higher LET (linear energy transfer) and more concentrated dose deposition of alpha particles. For more on alpha-PSMA see our alpha-PSMA guide.

Supportive measures for Pluvicto-related xerostomia include staying well-hydrated, sucking on ice chips, sugar-free chewing gum, artificial saliva preparations, and avoidance of alcohol-containing mouthwashes. For persistent dry mouth, a dental review is recommended because reduced salivary function increases risk of dental caries^[8].

Long-term effects — what is known and what is uncertain

Long-term safety data for Pluvicto are still maturing, but several patterns are emerging^[9]:

Myelodysplastic syndrome (MDS) and acute leukaemia — reported in approximately 1.5 percent combined cumulative incidence in longer-followed PRRT cohorts; somewhat smaller numbers in Pluvicto-specific data given the shorter observation time^[10]. Annual blood count surveillance for at least 5 years after the final cycle is standard.
Renal effects — Grade 3-4 renal events occurred in 3.4 percent of VISION patients^[2]. Long-term gradual decline in kidney function is uncommon with current dosing protocols but warrants annual monitoring.
Fertility — Pluvicto can damage germ cells; the FDA prescribing information recommends contraception for male patients during treatment and for 14 weeks after the final dose^[1].
Persistent fatigue — fatigue typically resolves over weeks-to-months after the final cycle but a small proportion of patients describe a slower recovery extending several months.

How Pluvicto is delivered — the practical course

The standard Pluvicto course is up to 6 cycles, with each cycle approximately 6 weeks apart^[1]:

Per-cycle dose — 7.4 GBq (200 mCi) administered intravenously over 5-10 minutes.
Cycle interval — typically every 6 weeks; can be extended to 10 weeks if blood counts require recovery.
Setting — most centres deliver as an outpatient day procedure with the patient discharged the same day; some centres prefer overnight admission for radiation-safety monitoring.
Radiation safety — patients are mildly radioactive for the first 5-7 days after each cycle. Standard guidance includes ~1 metre distance from young children and pregnant women, separate sleeping arrangements where possible, and standard toilet hygiene^[11].
Monitoring between cycles — blood counts (FBC), kidney function, and PSA before each cycle. Mid-treatment and final-response PSMA PET-CT and cross-sectional imaging at defined timepoints.

For day-by-day expectations of recovery between cycles, see our recovery time guide — the PRRT recovery framework applies broadly to Pluvicto as well.

The bottom line

Pluvicto is FDA-approved for adult patients with PSMA-positive mCRPC who have progressed on at least one ARPI; since March 2025, prior chemotherapy is no longer required following the PSMAfore-based label expansion^[3].
Pluvicto improved median overall survival from 11.3 to 15.3 months in VISION and produced PSA50 response in 46% of patients (vs 7.1% on standard care)^[2].
The most common side effects are fatigue (43%), xerostomia (39%), nausea (35%), and anaemia (32%) — most mild-to-moderate. Grade 3-4 events are most commonly hematologic.
Long-term surveillance for MDS/leukaemia (annual blood counts for ≥ 5 years) and kidney function is standard.
Eligibility requires Ga-68 PSMA-11 or F-18 piflufolastat PSMA PET-CT confirmation, multidisciplinary review, and signed consent.

Important

This article is general medical information for patient education. Pluvicto eligibility and treatment decisions require individualised review by your nuclear medicine and oncology teams, including PSMA PET-CT imaging, organ function assessment, and discussion of treatment goals.

"When patients ask me 'what should I expect' from Pluvicto, my honest framing is: fatigue, dry mouth, and some impact on blood counts are common — but most of these are mild-to-moderate and most patients complete the full course feeling reasonably well. The published trial data are remarkably clear on this. The bigger conversation is rarely about side effects; it is about realistic expectations of disease control. Pluvicto extends survival meaningfully for many patients; it is not a cure."

Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI

Pluvicto consultation · candidacy & expectations

If you are considering Pluvicto for metastatic castration-resistant prostate cancer, FMRI's nuclear medicine team can review your specific case — including PSMA PET-CT findings, prior treatments, organ function, and treatment goals — to help determine whether Pluvicto is appropriate and what to realistically expect.

Discuss Pluvicto for your case · WhatsApp +91 8800 988936

For patients & referring clinicians

Frequently asked questions

Q01 What is Pluvicto used for?

Pluvicto (Lu-177 vipivotide tetraxetan) is FDA-approved for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have progressed on at least one androgen-receptor pathway inhibitor (ARPI). The original 2022 approval also required prior taxane chemotherapy; the March 2025 PSMAfore-based update removed this requirement in selected patients [1][3].

Q02 How does Pluvicto work?

Pluvicto consists of two components: PSMA-617 (a small molecule that binds prostate-specific membrane antigen, PSMA, with high specificity on prostate cancer cells) and Lu-177 (a beta-emitting radionuclide with a half-life of 6.7 days). After intravenous infusion, Pluvicto selectively binds PSMA-positive cancer cells and delivers targeted radiation that damages cancer-cell DNA over several days [4]. The radiation range (~2.5 mm) is short enough to spare most surrounding healthy tissue.

Q03 What are the most common Pluvicto side effects?

From the VISION trial: fatigue (43% any grade, 5.9% Grade 3-4), dry mouth/xerostomia (39%, 0% Grade 3-4), nausea (35%, 1.3% Grade 3-4), anaemia (32%, 12.9% Grade 3-4), bone pain (27%, 4.0% Grade 3-4), and bone marrow suppression (thrombocytopenia 17%, lymphopenia 14%) [2]. The majority of events are mild-to-moderate.

Q04 Does Pluvicto cause hair loss?

No — Pluvicto does not typically cause hair loss. The targeted-radioligand mechanism means radiation is delivered specifically to PSMA-expressing cancer cells rather than the systemic distribution that produces chemotherapy-associated alopecia. This is one of the meaningful quality-of-life advantages of Pluvicto over taxane chemotherapy [2].

Q05 How long do Pluvicto side effects last?

Most acute side effects (nausea, fatigue) resolve within 1-2 weeks of each cycle. Blood count effects reach their nadir at weeks 4-6 and recover by weeks 6-8. Cumulative fatigue across the course can take 2-3 months to fully resolve after the final cycle. Xerostomia in some patients can persist beyond treatment but is mostly mild-to-moderate. Long-term effects (MDS, leukaemia) have a combined cumulative incidence of approximately 1.5% over many years [10].

Q06 How many cycles of Pluvicto can I have?

The standard Pluvicto course is up to 6 cycles, each approximately 6 weeks apart [1]. The decision point is typically after cycle 4 — patients showing ongoing response and tolerability are considered for cycles 5-6; those showing progression or unacceptable toxicity stop earlier. The 6-cycle limit was the maximum in the VISION trial and remains the FDA-labelled course.

Q07 Is Pluvicto a cure for prostate cancer?

No — Pluvicto is a disease-control therapy for metastatic castration-resistant prostate cancer, not a cure. It significantly extends survival (median 15.3 vs 11.3 months in VISION) [2] and provides meaningful disease control for many patients, but mCRPC remains a challenging disease where the goal of systemic therapy is prolongation of life and quality of life rather than cure.

Q08 What is xerostomia and why does it happen with Pluvicto?

Xerostomia means dry mouth from reduced salivary function. Salivary glands express low levels of PSMA, which causes some of the Pluvicto radioligand to bind there and deliver radiation. In VISION, 39% of patients reported any-grade xerostomia, but no Grade 3-4 (severe) events occurred [2]. This is far less than the xerostomia seen with alpha-emitter Ac-225 PSMA-617 (where ~25% have Grade 3 xerostomia) [7]. Supportive care includes hydration, sugar-free gum, ice chips, artificial saliva, and dental review.

Q09 Can I have Pluvicto if I have not had chemotherapy?

Yes — since the FDA label expansion in March 2025 (based on the PSMAfore trial), Pluvicto can be used in adult patients with PSMA-positive mCRPC who have progressed on at least one ARPI, without requiring prior taxane chemotherapy [3]. This was a significant indication change; before March 2025, prior chemotherapy was a requirement.

Q10 How is Pluvicto administered?

Pluvicto is given as an intravenous infusion of 7.4 GBq (200 mCi) over 5-10 minutes per cycle, repeated every 6 weeks for up to 6 cycles [1]. Most centres deliver it as an outpatient day procedure with same-day discharge; some centres prefer overnight admission for radiation-safety monitoring. Patients are mildly radioactive for the first 5-7 days and follow standard radiation-safety guidance.

Q11 Are there long-term side effects of Pluvicto?

The most clinically important long-term concerns are: (1) myelodysplastic syndrome (MDS) and acute leukaemia, with combined cumulative incidence ~1.5% in longer-followed PRRT cohorts [10]; (2) gradual decline in kidney function, uncommon but possible; (3) fertility — Pluvicto can damage germ cells, so contraception is recommended for male patients during treatment and for 14 weeks after the final dose [1]. Annual blood count and kidney function monitoring is standard for at least 5 years after the final cycle.

Q12 Where can I get Pluvicto in India?

Pluvicto and equivalent Lu-177 PSMA-617 therapy is available at a small number of Indian tertiary centres with active nuclear medicine theranostics programmes, including FMRI Gurugram, AIIMS New Delhi, Tata Memorial, Apollo, and others. The Indian published experience is substantial and consistent with the international cohorts [12]. Delivery requires Ga-68 PSMA-11 PET-CT for eligibility, baseline organ function workup, and multidisciplinary review.

Citations & references

All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the FDA archive — open in a new tab to verify.

[1] U.S. Food and Drug Administration. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) prescribing information. View source ↗

[2] Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION). N Engl J Med. 2021;385(12):1091-103. View source ↗

[3] Sweeney CJ, Gillessen S, Rathkopf D, et al. ¹⁷⁷Lu-PSMA-617 in mCRPC before chemotherapy: PSMAfore phase III trial. N Engl J Med. 2024. View source ↗

[4] Banerjee S, Pillai MRA, Knapp FF (Russ). Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015;115(8):2934-2974. View source ↗

[5] Hofman MS, Violet J, Hicks RJ, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic CRPC (LuPSMA trial). Lancet Oncol. 2018;19(6):825-833. View source ↗

[6] Morris MJ, Castellano D, Herrmann K, et al. PSMAfore trial of ¹⁷⁷Lu-PSMA-617 in chemotherapy-naive mCRPC. Lancet. 2024;404:1227-1239. View source ↗

[7] Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-Therapy of Metastatic CRPC with ²²⁵Ac-PSMA-617: Swimmer-Plot Analysis. J Nucl Med. 2018;59(5):795-802. View source ↗

[8] Heck MM, Tauber R, Schwaiger S, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷Lu-PSMA-I&T in mCRPC. Eur Urol. 2019;75(6):920-926. View source ↗

[9] Violet J, Sandhu S, Iravani A, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617. J Nucl Med. 2020;61(6):857-865. View source ↗

[10] Bergsma H, van Lom K, Raaijmakers MHGP, et al. Persistent Hematologic Dysfunction After PRRT with ¹⁷⁷Lu-DOTATATE. J Nucl Med. 2018;59(3):452-458. View source ↗

[11] IAEA. Safety in Nuclear Medicine: A Practical Guide. IAEA Safety Standards Series. 2014. View source ↗

[12] Yadav MP, Ballal S, Tripathi M, et al. Long-term outcome of ¹⁷⁷Lu-PSMA-617 in mCRPC: Indian multi-center experience. Eur J Nucl Med Mol Imaging. 2020;47(2):420-430. View source ↗

[13] Hofman MS, Emmett L, Sandhu S, et al. [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in mCRPC (TheraP). Lancet. 2021;397(10276):797-804. View source ↗

[14] Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for CRPC: Updated Recommendations From PCWG3. J Clin Oncol. 2016;34(12):1402-1418. View source ↗

[15] Hofman MS, Lawrentschuk N, Francis RJ, et al. PSMA PET-CT in high-risk prostate cancer (proPSMA). Lancet. 2020;395(10231):1208-1216. View source ↗

[16] Fendler WP, Calais J, Eiber M, et al. Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncol. 2019;5(6):856-863. View source ↗

[17] Calais J, Czernin J. PSA Response to ¹⁷⁷Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2020;61(4):488-489. View source ↗

[18] Gafita A, Calais J, Grogan TR, et al. Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy. Lancet Oncol. 2021;22(8):1115-1125. View source ↗

[19] Sweeney CJ, Sartor AO, Morris MJ, et al. VISION trial Subgroup Analysis. J Clin Oncol. 2022;40(suppl 6):95. View source ↗

[20] Hofman MS, Emmett L, Sandhu S, et al. TheraP trial overall survival update. Lancet Oncol. 2023;24(1):99-107. View source ↗

[21] Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589-608. View source ↗

[22] Khreish F, Ezziddin S, Schreckenberger M, et al. ¹⁷⁷Lu-PSMA-617 radioligand therapy in mCRPC: response analysis. Eur J Nucl Med Mol Imaging. 2020;47(7):1597-1604. View source ↗

[23] Rathke H, Holland-Letz T, Mier W, et al. Response Prediction of ¹⁷⁷Lu-PSMA-617 Radioligand Therapy Using PSMA PET. J Nucl Med. 2020;61(11):1581-1587. View source ↗

[24] Tagawa ST, Sun M, Sartor AO, et al. Phase I study of ²²⁵Ac-J591 in mCRPC. J Clin Oncol. 2024;42(7):842-851. View source ↗

[25] Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226-235. View source ↗

[26] Emmett L, Subramaniam S, Crumbaker M, et al. ENZA-p trial: ¹⁷⁷Lu-PSMA-617 plus enzalutamide in mCRPC. Lancet Oncol. 2024;25(5):563-571. View source ↗

[27] Calais J, Czernin J, Cao M, et al. Patient Outcomes After ¹⁷⁷Lu-PSMA-617 Treatment. J Nucl Med. 2020;61(3):360-365. View source ↗

[28] Buteau JP, Martin AJ, Emmett L, et al. PSMA and FDG-PET as predictive and prognostic biomarkers (TheraP). Lancet Oncol. 2022;23(11):1389-1397. View source ↗

[29] Sartor O, Morris MJ, Krause B, et al. VISION trial extended follow-up. J Clin Oncol. 2023;41(suppl 6):117. View source ↗

[30] Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients. Eur J Nucl Med Mol Imaging. 2015;42(1):5-19. View source ↗

[31] Gillessen S, Bossi A, Davis ID, et al. Management of advanced prostate cancer: APCCC 2022. Eur Urol. 2023;83(3):267-293. View source ↗

[32] Seifert R, Seitzer K, Herrmann K, et al. PSMA PET/CT Parameters Predicting Overall Survival in ¹⁷⁷Lu-PSMA-617 Treatment. Theranostics. 2020;10(17):7812-7820. View source ↗

About the Author

Dr. Ishita B. Sen

MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York

Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.

Full profile → All publications Book a consult